Head-To-Head Survey: Tilray Brands (NASDAQ:TLRY) and Gyre Therapeutics (NASDAQ:GYRE)

Gyre Therapeutics (NASDAQ:GYRE) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Gyre Therapeutics and Tilray Brands, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2	0	1	0	1.67
Tilray Brands	1	3	2	1	2.43

Gyre Therapeutics presently has a consensus target price of $16.00, indicating a potential upside of 118.28%. Tilray Brands has a consensus target price of $7.00, indicating a potential upside of 71.99%. Given Gyre Therapeutics’ higher possible upside, research analysts plainly believe Gyre Therapeutics is more favorable than Tilray Brands.

Risk & Volatility

Gyre Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Profitability

This table compares Gyre Therapeutics and Tilray Brands’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Tilray Brands	-13.11%	-7.76%	-5.59%

Earnings & Valuation

This table compares Gyre Therapeutics and Tilray Brands”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59 million	7.01	$5.03 million	($0.21)	-34.90
Tilray Brands	$915.45 million	0.61	-$121.40 million	($1.08)	-3.77

Gyre Therapeutics has higher earnings, but lower revenue than Tilray Brands. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 9.3% of Tilray Brands shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Gyre Therapeutics beats Tilray Brands on 8 of the 14 factors compared between the two stocks.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.